Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Siddhartha DevarakondaSumithra SankararamanBrett H HerzogKathryn A GoldSaiama N WaqarJeffrey P WardVictoria M RaymondRichard B LanmanAadel A ChaudhuriTaofeek K OwonikokoBob T LiJohn T PoirierCharles M RudinRamaswamy GovindanDaniel MorgenszternPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Patients with relapsed SCLC rarely undergo biopsies for molecular testing and often require prompt treatment initiation. ctDNA testing is less invasive and capable of identifying alterations in relapsed disease in a clinically meaningful timeframe. ctDNA testing on an expanded gene panel has the potential to advance our knowledge of the mechanisms underlying treatment resistance in SCLC and aid in the development of novel treatment strategies.